Key Takeaways Nyxoah launched U.S. commercialization of its Genio system after FDA approval for sleep apnea therapy.The first U.S. patients have been implanted, highlighting strong surgeon enthusiasm and early payor support.Expanding hospital approvals and training programs position Nyxoah for accelerating commercial momentum.Nyxoah (NYXH) has begun its U.S. commercial rollout of the Genio system, following FDA approval for its leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA ...